Cambridge, United States
Valink Therapeutics, with its slogan "Making better ADCs," is pioneering the development of novel multivalent bispecific antibody-drug conjugates (bsADCs) designed to revolutionize the treatment of solid tumors and other critical health conditions. The company's innovative approach focuses on non-obvious target combinations that synergize uniquely to improve patient outcomes in Biotechnology, Health Care, and Health and Wellness sectors.
Founded in 2020, Valink operates out of strategic biotech hubs in Cambridge, MA, and London, UK. As a Y Combinator incubated spin-out from the University of Oxford, it has already secured over $20M in funding. Its last recorded financial influx was a Seed Round investment on May 28, 2021, contributed by Hoxton Ventures, TGM Ventures, and Magnet Venture.
With strong financial backing and cutting-edge research capabilities, Valink Therapeutics is strategically positioned to make significant strides in cancer therapy advancement.
